)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bioretec
Bioretec (BRETEC) investor relations material
Bioretec Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Q3 net sales rose 85.5% YoY to EUR 1.328m; Jan–Sep sales increased 30.8% to EUR 3.648m, with Q3 growth across all regions.
Jan–Sep adjusted sales margin improved to 69.0% from 57.5%, and net loss narrowed to EUR 6.517m from EUR 7.482m.
Financial highlights
Q3 EBITDA was EUR -1.746m vs. EUR -1.768m; EBIT was EUR -1.806m vs. EUR -1.823m; net loss was EUR 1.839m vs. EUR 1.854m.
Jan–Sep EBITDA was EUR -5.371m vs. EUR -6.325m; EBIT was EUR -5.552m vs. EUR -6.483m.
Cash and cash equivalents were EUR 9.251m at period-end, vs. EUR 7.263m a year earlier and EUR 4.126m at year-end 2025.
Jan–Sep undiluted EPS was EUR -0.008 vs. EUR -0.28; diluted EPS was EUR -0.004 vs. EUR -0.22.
Outlook and guidance
2026–2028 targets: net sales above EUR 10m by end-2028 and average sales margin above 70% during the strategy period; targets depend on capital infusions and exclude potential partnership-driven acceleration.
Strategy targets at least one new product or indication every 12–18 months, expansion of the RemeOs portfolio, and stronger U.S. and OUS commercialization.
Near-term focus is sustaining sales growth and improving margins; spending is expected to remain stable and disciplined while advancing the pipeline. Product commercialization timing depends on regulatory approvals and R&D resource prioritization.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bioretec
- Innovative absorbable spinal cage targets major clinical needs in a large, growing market.BRETEC
Investor presentation - Absorbable implant innovation fuels 105% sales growth and global expansion in a $10B+ market.BRETECInvestor presentation
- H1 2026 saw double-digit sales growth, margin improvement, and a EUR 12.9 million capital raise.BRETECQ2 2026
- Adjusted sales margin rose to 70.1% as U.S. and European sales saw triple-digit growth.BRETECQ1 2026
- Net sales dropped 22.5% in 2025, but U.S. direct sales surged 60% quarter-over-quarter.BRETECQ4 2025
- Sales rose slightly, but losses deepened as strategy and commercialization shift.BRETECQ3 2025
- H1 2025 saw flat sales, a widened net loss, and a successful EUR 9M capital raise.BRETECQ2 2025
- Q3 2024 net sales up 42% year-over-year; U.S. and EU product launches drive future growth.BRETECQ3 2024
- Q1 2025 sales surged 105% as Bioretec accelerated global expansion and secured CE approval.BRETECQ1 2025
Next Bioretec earnings date
Q4 202612 Feb, 2027
Bioretec
Next Bioretec earnings date
Q4 202612 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bioretec Oy is a medical device manufacturer based in Finland, specializing in the development, manufacturing, and commercialization of bioresorbable orthopedic implants and implant materials. These products are designed for the treatment of bone and soft tissue injuries and are utilized in various surgical applications, including pediatrics, trauma surgery, and sports surgery. The company's Activa product line includes bioabsorbable biopolymer products. Bioretec Oy also has a subsidiary in Germany, BRI.Tech GmbH, and its products are used globally. The company is headquartered in Finland, and its shares are listed on the Nasdaq Helsinki.